Astrana Health, Inc. Hits New 52-Week High of USD 45.08

Astrana Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 45.08 on June 29, 2026. This achievement underscores the company's strong performance in the miscellaneous industry, where it has demonstrated notable growth metrics. Over the past year, Astrana Health has recorded a return of 14.35%, which, while below the S&P 500's performance of 20.53%, reflects a solid trajectory for a small-cap company with a market capitalization of USD 1,362 million. The company's financial health is highlighted by a price-to-earnings (P/E) ratio of 58.00 and a return on equity (ROE) of 3.02%. Notably, Astrana Health is net-debt free, which positions it favorably in terms of financial stability. The company has also shown impressive growth in net sales, with an annual increase of 35.87%, and a remarkable net profit growth of 140.64% reported in March. With a strong operating cash flow of USD 166.03 million and cash and equivalents totaling USD 907.97 million, Astrana Health appears well-equipped for future endeavors. The stock's performance has been bolstered by high institutional holdings at 60.1%, indicating a robust interest from sophisticated investors.